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Chrysanthy IkonomidouAbstract
Matrix metalloproteinases are vital drivers of synaptic remodeling in health and disease. It is suggested that at early
stages of epileptogenesis, inhibition of matrix metalloproteinases may help ameliorate cell death, aberrant network
rewiring, and neuroinflammation and prevent development of epilepsy.
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Epilepsy is one of the world's oldest recognized disor-
ders, affecting around 50 million people worldwide. Des-
pite continuing advances in treatment options, 30% of
patients remain drug refractory. Annual costs associated
with epilepsy are immense; in Europe alone, they
amount to over €20 billion. In addition to the costs, the
social burden and increased risk of death associated with
the disease underline the urgent need to find ways to
prevent epilepsy.
The development of chronic epilepsy can be the result
of initial insults (e.g., tumor, infection, stroke, traumatic
brain injury), brain malformations (e.g., focal cortical
dysplasias, schizencephaly, and others), mutated genes
(genetic epilepsies), or a component of a neurodevelop-
mental or neurodegenerative disorder (e.g., fragile X syn-
drome, Rett syndrome, neuronal ceroid lipofuscinosis).
Often, there is a time lag between the first impact of the
triggering factor and the occurrence of the first sponta-
neous seizure. During this period, the brain is functio-
nally altered and primed to generate abnormal electrical
activity. This process, named epileptogenesis, can take
several years in humans and a few weeks in experimental
animal models to produce epilepsy [1]. Extensive net-
work modifications occur during epileptogenesis; they
are believed to play a key role in the construction of epi-
leptogenic circuits. Some of these alterations are a direct
consequence of the initial trigger; others evolve during
epileptogenesis. Cell death, aberrant synaptogenesis, and
synaptic plasticity and neuroinflammation constitute
three key mechanisms implicated in epileptogenesis.Correspondence: ikonomidou@neurology.wisc.edu
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in any medium, provided the original work is pClassical anticonvulsants are ineffective in preventing
the process of epileptogenesis. To date, there are no ef-
fective antiepileptogenic treatments [1].The role of the extracellular matrix in epileptogenesis
The extracellular matrix (ECM) occupies the space bet-
ween neurons and glial cells and regulates neuronal cell
development, activity, and growth. It contributes to the
structural stabilization of neuronal processes and synap-
tic contacts during the maturation of the central nervous
system. The remodeling of the ECM during development
and after central nervous system injuries affects neu-
ronal guidance, synaptic plasticity, and regeneration (see
review by Soleman et al. [2]).
Neurons and glial cells secrete diverse molecules that
contribute to the composition of the ECM. The quantity
of ECM relative to cell mass is very high during em-
bryonic development and declines towards the time of
birth, while the composition of matrix proteins also
changes. The adult ECM restricts major reorganization
of processes and axonal outgrowth through the diffe-
rential expression of molecules into adulthood, and the
appearance of cartilage-like structures called perineuro-
nal nets. Nevertheless, the adult central nervous system
(CNS) still retains a capacity to promote structural plas-
ticity in response to injury and blood-brain barrier dis-
ruption and matrix metalloproteinases (MMPs) play key
roles in that respect (see review by Soleman et al. [2]).Matrix metalloproteinases
A family of extracellular soluble or membrane bound neu-
tral proteases, cleave, and remodel the ECM (review by
Yong [3] and Rosenberg [4]). Their substrates include pro-
teinases, growth factors, cytokines, cell surface receptors,n Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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substrates by MMPs have been implicated in the regula-
tion of diverse biological processes under normal and
pathological conditions, including embryonic develop-
ment, wound repair, inflammatory and neurological dis-
eases, and cancer as well as spinal cord and brain injuries.
MMP expression and enzymatic activity markedly in-
crease in response to brain injury in the developing and
the adult brain [3].
MMPs are multidomain proteins named according to a
sequential numbering scheme (Figure 1). In humans, 24
MMP genes encode 23 distinct MMPs (two identical
genes located on chromosome 1 encode MMP23). MMPs
all possess an N-terminal signal peptide, an autoinhibitory
pro-domain, and a catalytic domain. Most MMPs also
possess a C-terminal haemopexin domain which con-
tributes to the target specificity of MMP proteolysis by
coordinating interactions with substrates. The haemo-
pexin domain mediates protein-protein interactions and
can anchor MMPs to other cell-surface proteins. MMPs
can also act as ligands through their haemopexin do-
main by binding to receptors (see review by Huntley [6]
and Rosenberg [4]).
The majority of MMPs are secreted into the ECM,
while seven MMPs are membrane-associated, anchored
by a type 1 or type 2 transmembrane domain or a glyco-
sylphosphatidylinositol (GPI) linkage.
MMPs are synthesized as inactive zymogens and acti-
vated by disruption of the cysteine-zinc bond through
other MMPs and serine proteases or via modification of
the thiol-group (oxidation or S-nitrosylation [7]). Al-
though MMP activity is mostly extracellular, some activeTable 1 MMP substrates in synapses
Target MMP Receptors/binding partners
ECM proteins
Laminin MMP2,3,7,9,11,12,19,25 Integrins




TNF-α MMP14,15,16 TNFR1, TNFR2
MMP1,2,3,7,8,9,12,13




N-Cadherin MMP24 N-Cadherin, catenin
β-Dystroglycan MMPs α-Dystroglycan, dystrophin
Ephrin-B2 MMPs EphB receptors
Adapted and modified from Ethel and Ethel [5].MMPs can be found in neuronal or glial nuclei in which
they may have transcription factor-like or DNA repair-
like activity. MMP activity is terminated in the brain
mostly by four secreted tissue inhibitors of metallopro-
teinases (TIMPs) (see review by Huntley [6]).
Higher MMP expression and activity in the developing
brain and MMP knockout studies reporting CNS defects
suggest that MMPs play crucial roles in neural develop-
ment. MMPs have been shown to control brain function
by regulating neurogenesis, cell migration, topographic
mapping, axon guidance, myelination, and synaptogene-
sis. More recently, MMPs have been suggested as regula-
tors of synaptic activity in hippocampus, learning, and
memory (review by Huntley [6]).
Among MMPs, MMP-2 and matrix metalloproteinase-9
(MMP-9) are most abundantly expressed in the brain.
MMP-9 is highly expressed in neuronal cell bodies and
dendrites. Growing data suggest the association of MMP-9
with dendritic spine remodeling, synaptic plasticity, and
learning and memory formation. Experimental evidence
further suggests that MMPs are involved in seizure-
induced cell death, breakdown of the blood-brain
barrier, neuroinflammation, and aberrant synaptic plasti-
city, all of which occur in the context of epileptogenesis
[3,4,8,9].
Actions of MMPs in the brain with potential relevance to
epileptogenesis
MMPs and cell death
Apart from the proteolysis of extracellular protein tar-
gets, MMPs also localize to various intracellular sites
and have intracellular actions which consist of themSynaptic effect
Synapse formation and remodeling, NMDA-R activity, hippocampal LTP
Hippocampal LTP
Synapse formation, hippocampal LTP, learning and memory
AMPA receptor trafficking, synaptic scaling
Hippocampal LTP, learning and memory
Cell survival
Synapse formation and stability, LTP
Hippocampal LTP
Synapse formation and stability, hippocampal LTP, learning and memory
Figure 1 Structure of matrix metalloproteinases (adopted and modified from Huntley [6]).
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brain injury during hypoxia, traumatic injury, and pro-
longed seizure activity. Increased activity of MMPs inclu-
ding MMP-2, MMP-9, and MMP-13 was demonstrated in
neuronal nuclei of brains at an early stage of ischemic
stroke and reperfusion injury [4,10]. The nucleus has a
matrix that resembles the ECM and provides structural
and organizational support for various nuclear processes
as well as apoptosis, which involves proteolytic processing
of nuclear proteins. The intranuclear gelatinase activity in
ischemic neurons suggests a possible role for gelatinases
in nuclear matrix proteolysis. Intranuclear MMP-2 and
MMP-9 activity was shown to facilitate oxidative injury in
neurons during early ischemic insult by cleaving nuclear
proteins poly-ADP-ribose polymerase 1 (PARP-1) and
X-ray cross-complementary factor 1 (XRCC1). Both PARP-1
and XRCC1 are DNA repair enzymes which become
activated following the induction of DNA damage. DNA
base excision repair machinery in neuronal nuclei repairs
oxidative DNA damage. DNA strand breaks induce
PARP-1 activity, which triggers DNA repair by binding to
damaged DNA. The cleavage of DNA repair proteins by
MMP activity in neuronal nuclei interferes with oxidative
DNA damage repair, which could contribute to neuronal
apoptosis. Mice overexpressing superoxide dismutase
(SOD) are protected from ischemic injury and have
reduced MMP production.
Activation of intracellular MMPs could be one of the
earliest pathological events triggered downstream of oxi-
dative stress. MMP inhibition may prove to be a novel
therapeutic strategy to prevent neuronal apoptotic injury
in the brain. A crucial role of MMPs in mediating neur-
onal death in the developing mammalian brain has been
demonstrated in animal models for traumatic, ischemic,
and epileptic brain damage [11,12].MMPs and synaptic plasticity
MMP-9 is required for late-phase long-term potentiation
(LTP) in the hippocampus [13] and prefrontal cortex [14]
and for spatial and emotional learning [13]. Bozdagi et al.
[15] and Tian et al. [16] demonstrated that LTP is asso-
ciated with significant increases in levels of MMP-9,
this effect being dependent upon N-methyl-D-aspartate
(NMDA) receptor activation. MMP-9 appears to exert its
action directly at the level of dendritic spines [8,16,17],
possibly via cleavage of synapse-associated molecules such
as dystroglycan [8,10] and intracellular adhesion molecule
5 (ICAM-5) [16].
Transsynaptic activation of NMDA receptors in neurons
leads to activation of the ERK1/2 and PI3 kinase pathways
[18]. The hypothesis has been formulated that, in the con-
text of evolving epilepsy, pathological transsynaptic acti-
vation of NMDA receptors leads to increased MMP-9
transcription via ERK1/2 and/or PI3 kinase-dependent
mechanisms [8]. MMP-9 sequentially remodels dendritic
spines within secondary epileptogenic foci in the neocor-
tex and eventually the hippocampus, partly via ICAM-5
and dystroglycan cleavage. MMP-9 may exert its effects
on integrins through the cleavage of laminin or other
ECM components, exposing otherwise inaccessible RGD
sites that can then induce integrin signaling. Synapse re-
modeling induced by MMPs can be blocked by the
NMDA receptor antagonist MK-801, indicating that
MMPs' effects are mediated through NMDA receptor ac-
tivity. In fact, NMDA receptor activity has been reported
to regulate MMP-9 protein levels and activity, which may
be a key step in LTP, the neurophysiological correlate of
learning and memory. MMP-9 knockout mice show
behavioral impairments in hippocampus-dependent asso-
ciative learning [13]. Furthermore, hippocampal slice cul-
tures from MMP-9 knockout mice show impaired LTP,
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MMP-9 [13].
MMP-7 has also been shown to modulate synapse
morphology. Active MMP-7 alters the morphology of
dendritic spines, inducing their elongation and remo-
deling. MMP-7 is derived from macrophages and is
present at sites of tissue repair and remodeling. MMP-7
can process pro-MMP-9 into the fully active form and
may exert its effects on synapses through activation of
neuron-derived MMP-9.
MMP-24 is another potential regulator of synapse for-
mation and remodeling, as it is developmentally regulated
in the cerebellum and hippocampus and is also found in
the adult brain. It is expressed in neurons and may
regulate axon growth and dendrite extension. MMP-24
interacts with synaptic scaffold proteins, AMPA receptor
binding protein (ABP) and glutamate receptor interacting
protein (GRIP) at synaptic sites. Because of the furin
cleavage sites, MMP-24 appears on the cell surface in an
active form and may thus affect synapse remodeling by
cleaving cell adhesion molecules within and around CNS
synapses (reviewed by Huntley [6]).
MMPS and neuroinflammation
The blood-brain barrier (BBB), a unique feature of the
cerebral vasculature, is gaining attention as a feature in
common neurologic disorders including epilepsy. Although
acute blood-brain barrier dysfunction can induce cerebral
edema, seizures, or neuropsychiatric symptoms, epilepto-
genesis and cognitive decline are among the chronic
effects (reviewed by Rosenberg [10] and Schoknecht and
Shalev [19]).
BBB dysfunction acutely promotes single seizures, facili-
tates the development of epilepsy in animal models, and
furthermore was observed in patients with mesial tem-
poral lobe epilepsy. Signaling cascades modulating BBB
properties may become future targets to prevent seizures
and epileptogenesis. Blocking transforming growth factor
β (TGF-β) receptors reduced albumin-mediated epilepto-
genesis, suggesting TGF-β signaling to mediate down-
stream events following focal neocortical BBB opening
that led to albumin extravasation and epileptogenesis.
Microarray analysis further revealed that focal BBB ope-
ning and topical application of albumin and TGF-β simi-
larly induced astrocytic activation, downregulated genes
related to γ-aminobutyric acid (GABA) ergic signaling,
and led to an inflammatory response. Astrocytic activation
leads to altered extracellular homeostasis including im-
paired potassium buffering and glutamate metabolism,
consequently increasing neuronal excitability. Inflamma-
tory mediators such as tumor necrosis factor α (TNF-α),
interleukin (Il)-6, and IL-1β have promoted seizures and
epileptogenesis. In preliminary studies, patients have
responded to antiinflammatory treatment with reducedseizure frequency, thus highlighting the immune response
as a target for therapeutic interventions (reviewed by
Rosenberg [10] and Schoknecht and Shalev [19]).
There is ample evidence to suggest that MMPs are key
players in enhancing BBB permeability in the context of
brain insults and, by doing so, promoting neuroinflam-
mation. The basal lamina around cerebral blood vessels
contains extracellular matrix proteins, including laminin,
fibronectin, heparan sulfate, and type IV collagen. Pro-
teolysis of the blood-brain barrier by MMPs results in
loss of basal lamina proteins. MMP-2, MMP-3 and
MMP-9 increase the permeability of the blood-brain
barrier, and inhibitors of MMPs can reduce damage to
the blood-brain barrier. In an Mmp9 knockout model,
focal ischemic lesions decreased the damage to the
blood-brain barrier and the infarct size.
MMP3 is an inducible enzyme and its concentration in-
creases in hypoxia-ischemia and immunological reactions.
WhenMmp3 is knocked out, the normal disruption of the
blood-brain barrier that occurs after intracerebral injection
of lipopolysaccharide is attenuated. Mmp3 knockout mice
have fewer neutrophils recruited to the site of inflamma-
tion than do wild-type mice (reviewed by Rosenberg [10]
and Schoknecht and Shalev [19]).
The role of MMPs in animal models of epileptogenesis
Recent data indicate an involvement of extracellular prote-
olysis in the pathogenesis of epilepsy. Activation of MMP-2
and MMP-9 occurs in the brain in the kainic acid rat
seizure model. Particularly intriguing is the evidence for a
role of the matrix metalloproteinase-9 (MMP-9). Several
studies have shown robust activation of MMP-9 by
seizure-evoking stimuli. The first crucial study linking
MMP-9 to epileptogenesis was published by Wilczynski
et al. [8]. MMP-9 was found to promote epileptogenesis in
kainate-evoked and pentylenetetrazole-kindling-induced
epilepsy in rats and mice. In two animal models of tem-
poral lobe epilepsy, the kainic acid model and the
pentylenetetrazole kindling model, these authors demon-
strated decreased sensitivity in MMP-9 knockout mice
but increased sensitivity in transgenic rats overexpressing
MMP-9. By means of immuno-electron microscopy, it
was shown that MMP-9 associates with hippocampal den-
dritic spines bearing asymmetrical (excitatory) synapses.
Both the MMP-9 protein levels and enzymatic activity
strongly increase upon seizures. MMP-9 deficiency in
MMP-9 knockout mice diminished seizure-evoked pru-
ning of dendritic spines and decreased aberrant synapto-
genesis and mossy fiber sprouting. The observations that
aberrant synaptic plasticity contributes to epileptogenesis
and that MMP-9 is a key molecule for synaptic plasticity
acting via β1 integrins suggest that MMP-9 could play a
crucial role in epileptogenesis through a similar mecha-
nism (Huntley [6]).
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in children following febrile seizures. Prolonged seizures
were associated with high serum MMP-9 levels and
increases in the ratio of MMP-9 to TIMP-1 in patients
with acute encephalopathy with dysfunction of the
blood-brain barrier following prolonged febrile seizures
[20]. MMP-9 protein levels were elevated in cortical le-
sions in patients with focal cortical dysplasia type IIb
and tuberous sclerosis complex, which cause chronic
epilepsy in children, suggesting a possible pathological
role for MMP-9 in these intractable conditions. Another
study showed that the MMP-9 levels in cerebrospinal
fluid were higher in patients with bacterial meningitis
who developed secondary epilepsy than in individuals
who recovered without neurological deficits, suggesting
that MMP-9 concentrations contribute to postmeningi-
tic neurological sequelae (reviewed by Mizoguchi and
Yamada [21]).
Summary and conclusions
To date, there is no armamentarium available to prevent
the development of epilepsy. Antiepileptic treatments do
not influence epileptogenesis. The ECM is gaining in-
creasing attention as a compartment in which remo-
deling programs primarily destined to operate during
development are reactivated following injurious insults
and contribute to aberrant rewiring of neuronal net-
works that results in pathologically increased excitability
and the development of epilepsy.
In this minireview, evidence for the role of a class of
enzymes, the MMPs, in mediation of cell death, aberrant
synaptic plasticity, and neuroinflammation in the mam-
malian brain is presented briefly with appropriate refe-
rence to more extensive reviews.
The suggestion is presented that at early stages of epi-
leptogenesis, it could be beneficial to prevent neural net-
work rewiring and resulting ECM remodeling via the
inhibition of MMPs. Since MMPs and other ECM ecto-
proteases also play crucial roles in neurologic recovery,
the major challenge will be to direct reactivated struc-
tural plasticity in the ‘right’ direction. For that, it will be
critical to determine how MMP activity transitions from
its normal role in synaptic circuit remodeling to its aber-
rant and deleterious roles that lead to epilepsy.
A large number of MMP inhibitors have been developed
in the past 30 years for the treatment of metastatic cancer,
and several generations of synthetic MMP inhibitors were
tested in clinical trials since the 1990s [22]. These include
the first-generation peptidomimetics (such as Batimastat
and Marimastat), the second-generation nonpeptido-
mimetics (such as Tanomastat and Prinomastat), and the
third-generation tetracycline derivatives (such as Minocy-
cline and Metastat). Despite encouraging preclinical data
in cancer, clinical trials were unsuccessful mainly becauseof the lack of overall response and the presence of dose-
limiting toxicity. Consequently, all clinical trials on the use
of synthetic MMPIs in cancer have been terminated [23].
The information presented in this minireview suggests a
potential new field of application for these agents. Testing
of available MMP inhibitors in preclinical models of epi-
leptogenesis has not been pursued so far and seems to be
the next most logical step to determine whether MMP in-
hibition may constitute a promising antiepileptogenic
strategy.
Competing interests
The authors declare that they have no competing interests.
Received: 31 March 2014 Accepted: 13 August 2014
References
1. Goldberg EM, Coulter DA (2013) Mechanisms of epileptogenesis: a
convergence on neural circuit dysfunction. Nat Rev Neurosci 14:337–349
2. Soleman S, Filipov MA, Dityatev A, Fawcett JW (2013) Targeting the
neural extracellular matrix in neurological disorders. Neuroscience
253:194–213
3. Yong VW (2005) Metalloproteinases: mediators of pathology and
regeneration in the CNS. Nat Rev Neurosci 6:931–944
4. Rosenberg GA (2009) Matrix metalloproteinases and their multiple roles in
neurodegenerative diseases. Lancet Neurol 8:205–216
5. Ethel IM, Ethel DW (2007) Matrix metalloproteinases in brain development and
remodeling: synaptic functions and targets. J Neurosci Res 85:2813–2823
6. Huntley GW (2012) Synaptic circuit remodeling by matrix
metalloproteinases in health and disease. Nat Rev Neurosci 13:743–754
7. Gu Z, Kaul M, Yan B, Kridel SJ, Cui J, Strongin A, Smith JW, Liddington RC,
Lipton SA (2002) S-nitrosylation of matrix metalloproteinases: signaling
pathway to neuronal cell death. Science 297:1186–1190
8. Wilczynski GM, Konopacki FA, Wilczek E, Lasiecka Z, Gorlewicz A, Michaluk P,
Wawrzyniak M, Malinowska M, Okulski P, Kolodziej LR, Konopka W, Duniec K,
Mioduszewska B, Nikolaev E, Walczak A, Owczarek D, Gorecki DC,
Zuschratter W, Ottersen OP, Kaczmarek L (2008) Important role of matrix
metalloproteinase-9 in epileptogenesis. J Cell Biol 10180:1021–1035
9. Yan Y, Hill YW, Rosenberg GA (2011) Multiple roles of metalloproteinases in
neurological disorders. Prog Mol Biol 99:241–263
10. Rosenberg GA (2012) Neurological diseases in relation to the blood-brain
barrier. J Cereb Blood Flow Metab 32:1139–1151
11. Sifringer M, Stefovska V, Zentner I, Hansen B, Stepulak A, Knaute C, Marzahn
J, Ikonomidou C (2007) The role of matrix metalloproteinases in infant
traumatic brain injury. Neurobiol Dis 25:526–535
12. Hoehna Y, Uckermann O, Luksch H, Stefovska V, Marzahn J, Theil M,
Gorkiewicz T, Gawlak M, Wilczynski GM, Kaczmarek L, Ikonomidou C (2012)
Matrix metalloproteinase 9 regulates cell death following pilocarpine-
induced seizures in the developing brain. Neurobiol Dis 48:339–347
13. Nagy V, Bozdagi O, Matynia A, Balcerzyk M, Okulski P, Dzwonek J, Costa RM,
Silva AJ, Kaczmarek L, Huntley GW (2006) Matrix metalloproteinase-9 is
required for hippocampal late-phase long-term potentiation and memory.
J Neurosci 26:1923–1934
14. Okulski P, Jay TM, Jaworski J, Duniec K, Dzwonek J, Konopacki FA, Wilczynski
GM, Sánchez-Capelo A, Mallet J, Kaczmarek L (2007) TIMP-1 abolishes
MMP-9-dependent long-lasting long-term potentiation in the prefrontal
cortex. Biol Psychiatry 62:359–362
15. Bozdagi O, Nagy V, Kwei KT, Huntley GW (2007) In vivo roles for matrix
metalloproteinase-9 in mature hippocampal synaptic physiology and
plasticity. J Neurophysiol 98:334–344
16. Tian L, Stefanidakis M, Ning L, Van Lint P, Nyman-Huttunen H, Libert C,
Itohara S, Mishina M, Rauvala H, Gahmberg CG (2007) Activation of NMDA
receptors promotes dendritic spine development through MMP-mediated
ICAM-5 cleavage. J Cell Biol 178:687–700
17. Konopacki FA, Rylski M, Wilczek E, Amborska R, Detka D, Kaczmarek L,
Wilczynski GM (2007) Synaptic localization of seizure-induced matrix
metalloproteinase-9 mRNA. Neuroscience 150:31–39
Ikonomidou Molecular and Cellular Pediatrics 2014, 1:6 Page 6 of 6
http://www.molcellped.com/content/1/1/618. Papadia S, Hardingham GE (2007) The dichotomy of NMDA receptor
signaling. Neuroscientist 13:572–579
19. Schoknecht K, Shalev H (2012) Blood-brain barrier dysfunction in brain
diseases: clinical experience. Epilepsia 6:7–13
20. Suenaga N, Ichiyama T, Kubota M, Isumi H, Tohyama J, Furukawa S (2008)
Roles of matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases
1 in acute encephalopathy following prolonged febrile seizures. J Neurol Sci
266:126–130
21. Mizoguchi H, Yamada K (2013) Roles of matrix metalloproteinases and their
targets in epileptogenesis and seizures. Clin Psychopharmacol Neurosci
11:45–52
22. Deng X, He G, Liu J, Luo F, Peng X, Tang S, Gao Z, Lin Q, Keller JM, Yang T,
Keller ET (2014) Recent advances in bone-targeted therapies of metastatic
prostate cancer. Cancer Treat Rev 40:730–738
23. Stellas D, Patsavoudi E (2012) Inhibiting matrix metalloproteinases, an old
story with new potentials for cancer treatment. Anticancer Agents Med
Chem 12:707–717
doi:10.1186/s40348-014-0006-y
Cite this article as: Ikonomidou: Matrix metalloproteinases and
epileptogenesis. Molecular and Cellular Pediatrics 2014 1:6.Submit your manuscript to a 
journal and beneﬁ t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the ﬁ eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
